Repurposing approved drugs targeting Leishmania infantum 5-Methylthioadenosine Phosphorylase as anti-leishmanial candidates
Frontiers in Cellular and Infection Microbiology · 13.03.2026 · 16
DOI: 10.3389/fcimb.2026.1787791 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 13.03.2026. Verfasst von Yosser Zina Abdelkrim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Epidemiology and Experimental Pathology (LR11IPT04/LR16IPT04), Institut Pasteur de Tunis - University Tunis El Manar, Tunis, …. Hauptthemen laut MEDLINE: Leishmania infantum, Purine-Nucleoside Phosphorylase, Antiprotozoal Agents, Drug Repositioning. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Drug repurposing is a promising strategy for identifying new treatments against neglected tropical diseases such as leishmaniases, which are endemic in Asia, Africa, the Americas, and Southern Europe, offering the advantages of reduced development time and cost. In this context, computational and biochemical investigation of therapeutic targets plays a key role in guiding the selection of effective drug candidates.
Methods
In this study, we investigated Leishmania infantum 5′-methylthioadenosine phosphorylase (LiMTAP) as a potential drug target by evaluating criteria defining such targets, including assayability, biochemical properties, and structural features enabling inhibitor selection. Trimeric 3D models of Li MTAP were generated, followed by virtual screening and docking of FDA-approved drugs. A robust miniaturized robotic assay was developed for recombinant Li MTAP to enable biochemical validation. Seven predicted drug candidates were subsequently tested in enzymatic and biological assays.
Results
Two compounds—Labetalol and Halofuginone—inhibited Li MTAP activity with IC₅₀ values ranging from 200–400 µg/mL. The antileishmanial activity of all seven compounds was evaluated on extracellular promastigotes; four compounds (Dobutamine, Halofuginone, Labetalol, and Pentamidine) showed activity. Pentamidine and Dobutamine did not inhibit Li MTAP despite their anti-promastigote effects. Labetalol exhibited an IC 50 of 29.67 µg/mL against extracellular promastigotes and showed no significant toxicity on THP-1 macrophages at effective doses (CC 50 = 98.29 µg/mL). When tested on intracellular amastigotes, Labetalol demonstrated an IC 50 value of 19.10 µg/mL.
Discussion
This study confirms the in silico predictions through in vitro validation and highlights repurposed drugs as promising anti- Leishmania candidates .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Epidemiology and Experimental Pathology (LR11IPT04/LR16IPT04), Institut Pasteur de Tunis - University Tunis El Manar, Tunis, Tunisia.
- Process Engineering Department, Institut Supérieur des Etudes Technologiques de Bizerte, Direction Générale des Etudes Technologiques, Tunis, Tunisia.
Zitieren
APA
Abdelkrim, Y. Z., Oualha, R., Abbes, S., Khalfaoui, I., Mejri, T., Barhoumi, M., Abid, H., Harigua-Souiai, E., & Guizani, I. (2026). Repurposing approved drugs targeting Leishmania infantum 5-Methylthioadenosine Phosphorylase as anti-leishmanial candidates. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1787791
Vancouver
Abdelkrim YZ, Oualha R, Abbes S, Khalfaoui I, Mejri T, Barhoumi M, et al. Repurposing approved drugs targeting Leishmania infantum 5-Methylthioadenosine Phosphorylase as anti-leishmanial candidates. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1787791
BibTeX
@article{Abdelkrim2026,
author = {Abdelkrim, Yosser Zina and Oualha, Rafeh and Abbes, Sonia and Khalfaoui, Isleme and Mejri, Thouraya and Barhoumi, Mourad and Abid, Hela and Harigua-Souiai, Emna and Guizani, Ikram},
title = {Repurposing approved drugs targeting Leishmania infantum 5-Methylthioadenosine Phosphorylase as anti-leishmanial candidates},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1787791}
}
EUVIMED